MSN Labs launches renal cancer treatment Cabolong
Hyderabad: MSN Labs, a city-based pharma company on Thursday announced the launch of Cabolong, a branded generic of Cabozantinib for treatment of renal cell carcinoma.
The company's new Oncology Division will focus on presenting a comprehensive range of affordable high quality, bio-equivalent generic cancer drugs benefitting patients in the country, MSN labs said in a press release.
"Our endeavour at MSN Labs has always been to enable swift access to affordable life-saving medicines in critical therapeutic domains. Given the rising cancer incidence in our country and overwhelming treatment costs associated with it, launch of our dedicated oncology division demonstrates our unwavering commitment to patients' health and economic well-being." MSN Group said in a statement as reported by PTI.
Cabolong is manufactured at MSN Labs' state-of-the-art facility approved by stringent global regulatory authorities like US FDA and EU GMP, it added.
MSN Laboratories had earlier entered into a licence agreement with the Defence Research & Development Establishment (DRDE) for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG), used for the treatment of COVID-19.
Read also: MSN Labs, DRDE ink pact for COVID drug 2-DG
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.